Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study

Keyphrases

• Weight Loss 100%
• Non-diabetic Obese 100%
• Obese Patients 100%
• Erectile Dysfunction 100%
• Database Study 100%
• Semaglutide 100%
• TriNetX 100%
• Obese Men 40%
• Non-diabetic 30%
• Phosphodiesterase Type 5 Inhibitors 30%
• Confidence Interval 30%
• Diabetic Men 30%
• Testosterone Deficiency 30%
• Diabetes Diagnosis 20%
• Insulin 10%
• Testosterone 10%
• Pulmonary Hypertension 10%
• Sexual Dysfunction 10%
• Hemoglobin A1c (HbA1c) 10%
• Risk Ratio 10%
• Metformin 10%
• Package Insert 10%
• Radical Prostatectomy 10%
• Pelvic Radiation 10%
• Intracavernosal Injection 10%
• Penile Prosthesis 10%
• Deficiency Diagnosis 10%

Medicine and Dentistry

• Diabetic Obesity 100%
• Erectile Dysfunction 100%
• Semaglutide 100%
• Diabetes Mellitus 40%
• Androgen Deficiency 30%
• Phosphodiesterase V Inhibitor 30%
• Body Mass Index 20%
• Diabetes 10%
• Pulmonary Hypertension 10%
• Pelvis 10%
• Prostatectomy 10%
• Glycon 10%
• Hemoglobin A1c 10%
• Intracavernous Injection 10%
• Penile prosthesis 10%
• Erectile Dysfunction Diagnosis 10%
• Primary Outcome 10%
• Side Effect 10%
• Sexual Dysfunction 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Diabetic Obesity 100%
• Erectile Dysfunction 100%
• Semaglutide 100%
• Diabetes Mellitus 40%
• Phosphodiesterase V Inhibitor 30%
• Androgen Deficiency 30%
• Pulmonary Hypertension 10%
• Hemoglobin A1c 10%
• Metformin 10%
• Intracavernous Injection 10%
• Side Effect 10%
• Sexual Dysfunction 10%